GlassScriptPhysician profile
John Lawrence Freiberg
NPI 1609812791
$1,380.25
in general payments reported to CMS, 2019-2025
21 companies · $86.26 in 2025
The $86.26 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $419 · 2021: $137 · 2022: $15.91 · 2023: $153 · 2024: $89.41 · 2025: $86.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $275.82 | 2019-2025 | Briviact |
| Supernus Pharmaceuticals, INC. | $169.55 | 2020 | |
| Alexion Pharmaceuticals, INC. | $137.03 | 2019-2020 | |
| Silk Road Medical, INC. | $91.92 | 2019 | |
| Abbvie INC. | $85.56 | 2023-2025 | |
| Allergan, INC. | $76.71 | 2019-2020 | |
| Eisai INC. | $58.35 | 2020-2022 | |
| Genzyme Corporation | $56.65 | 2019 | |
| Neurelis, INC. | $56.28 | 2020-2025 | Valtoco |
| Amgen INC. | $50.92 | 2019-2025 | Uplizna |
| Argenx US, INC. | $42.80 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $40.10 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $40.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $37.54 | 2021 | |
| Sk Life Science, INC. | $37.43 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $34.01 | 2019-2020 | |
| Horizon Therapeutics Plc | $22.87 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.65 | 2019 | |
| Pfizer INC. | $15.85 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2024 | Andexxa |
| Boston Scientific Corporation | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Freiberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.